In 2025 at ASCO, we presented the five-year follow-up of the ARCHES trial. The ARCHES trial randomized patients with metastatic hormone-sensitive prostate cancer to androgen deprivation therapy and placebo or enzalutamide plus androgen deprivation therapy. The ARCHES trial many years ago, about five years ago now, led to the FDA approval of this regimen because it delayed progression-free survival by over 60% and two years later we showed that this combination improved overall survival in 2021...
In 2025 at ASCO, we presented the five-year follow-up of the ARCHES trial. The ARCHES trial randomized patients with metastatic hormone-sensitive prostate cancer to androgen deprivation therapy and placebo or enzalutamide plus androgen deprivation therapy. The ARCHES trial many years ago, about five years ago now, led to the FDA approval of this regimen because it delayed progression-free survival by over 60% and two years later we showed that this combination improved overall survival in 2021. This five-year update really extends these findings to ask the question of how long are these men living, how much longer are they living, what are their outcomes five years later and we show that for high-volume patients survival is extended by a median of three years from about four to seven years. That’s a phenomenal result for these patients, particularly with de novo or synchronous metastatic disease. The absolute survival benefit for the overall ARCHES trial was 13% additional, from about 53 to 66% chance of being alive at five years. This extension of survival at five years was notable for low-volume, high-volume patients, regardless of whether a patient had had prior docetaxel chemotherapy and regardless of geography, age, and other disease characteristics.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
